nach oben

Current Psychiatry Reports

Erschienen in:

01.10.2012 | Attention-Deficit Disorder (R Bussing, Section Editor)

Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment

verfasst von: Nikki Ivanchak, Kristen Fletcher, Gregory A. Jicha

Erschienen in: Current Psychiatry Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Attentional deficits are frequently seen in isolation as the presenting sign and symptom of neurodegenerative disease, manifest as mild cognitive impairment (MCI). Persistent ADHD in the geriatric population could well be misconstrued as MCI, leading to the incorrect assumption that such persons are succumbing to a neurodegenerative disease process. Alternatively, the molecular, neuroanatomic, or neurochemical abnormalities seen in ADHD may contribute to the development of de novo late life neurodegenerative disease. The present review examines the issue of causality vs confound regarding the association of ADHD with MCI, suggesting that both are tenable hypotheses.

Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59:1439–43.

Freitag CM, Rohde LA, Lempp T, et al. Phenotypic and measurement influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry. 2010;19:311–23.PubMedCrossRef

• Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122:97–109. This general review of ADHD across the lifespan can help orient the reader to current clinical conceptualization and medical practice of this disorder. The general overview of practical clinical information for diagnosis and treatment is comprehensive and yet understandable for the lay practitioner that lacks specific expertise in the area of ADHD.PubMedCrossRef

Kleschevnikov AM, Belichenko PV, Salehi A, et al. Discoveries in down syndrome: moving basic science to clinical care. Prog Brain Res. 2012;197:199–221.PubMedCrossRef

Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil. 2009;30:827–38.PubMedCrossRef

Jicha GAaP, R.C. Mild cognitive impairment. In: Growdon JaR, M, editors. The dementias 2. Massachusetts: Elsevier Inc; 2007.

Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22–31.PubMedCrossRef

Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef

Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133–42.PubMedCrossRef

10.

Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Int Med. 2004;256:240–6.CrossRef

11.

Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104–13.PubMed

12.

Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry. 1985;24:211–20.CrossRef

13.

Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57:1442–51.PubMedCrossRef

14.

Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716–23.PubMedCrossRef

15.

•• Ivanchak N, Abner EL, Carr SA, et al. Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res 2011. doi:10.4061/2011/729801. This manuscript represents the first and only published report on the association of childhood ADHD with the development of late-life mild cognitive impairment. The findings demonstrate the persistence of ADHD traits well into geriatric years, as evidenced by specific attentional deficits on neuropsychological tests. Importantly, the authors found no association between ADHD and the diagnosis of MCI or Alzheimer’s disease, suggesting that late life cognitive decline is independent of the early childhood manifestations and late life persistence of ADHD traits.

16.

Diagnostic and statistical manual of mental disorders. Washington, D.C.: American Psychiatric Association. 1994.

17.

Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885–90.PubMed

18.

Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2000;157:1156–9.PubMedCrossRef

19.

Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:857–70. vi.PubMedCrossRef

20.

Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry. 2004;65(Suppl):12–7.PubMed

21.

Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am. 1999;46:915–27. vii.PubMedCrossRef

22.

Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scale. Arch Gen Psychiatry. 2010;67:1168–78.PubMedCrossRef

23.

Primich C, Iennaco J. Diagnosing adult attention-deficit hyperactivity disorder: the importance of establishing daily life contexts for symptoms and impairments. J Psychiatr Ment Health Nurs. 2012;19:362–73.PubMedCrossRef

24.

Konrad K, Eickhoff SB. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp. 2010;31:904–16.PubMedCrossRef

25.

Ivanchak N, Abner EL, Carr SA, et al. Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res. 2011;2011:729801.PubMed

26.

Bramham J, Murphy DG, Xenitidis K, et al. Adults with attention deficit hyperactivity disorder: an investigation of age-related differences in behavioral symptoms, neuropsychological function and co-morbidity. Psychol Med. 2012. doi:10.1017/S0033291712000219.

27.

Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(Suppl):3–7.PubMed

28.

McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162:1621–7.PubMedCrossRef

29.

Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792–8.PubMed

30.

Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996;62:213–9.PubMedCrossRef

31.

Van Ameringen M, Mancini C, Simpson W, et al. Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011;17:221–6.PubMedCrossRef

32.

Biederman J, Ball SW, Monuteaux MC, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry. 2008;47:426–34.PubMedCrossRef

33.

Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry. 1996;37:393–401.PubMedCrossRef

34.

Hennessey KA, Stein MD, Rosengard C, et al. Childhood attention deficit hyperactivity disorder, substance use, and adult functioning among incarcerated women. J Atten Disord. 2010;14:273–80.PubMedCrossRef

35.

Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75:889–97.PubMedCrossRef

36.

Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7:80–93.PubMedCrossRef

37.

Busse A, Bischkopf J, Riedel-Heller SG, et al. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med. 2003;33:1029–38.PubMedCrossRef

38.

Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European consortium on Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77:714–8.PubMedCrossRef

39.

Stephan BC, Matthews FE, McKeith IG, et al. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc. 2007;55:1534–40.PubMedCrossRef

40.

Jicha GA, Abner E, Schmitt FA, et al. Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord. 2008;26:187–92.PubMedCrossRef

41.

•• Golimstok A, Rojas JI, Romano M, et al. Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: a case-control study. Eur J Neurol. 2011;18:78–84. The data presented suggest an association between childhood ADHD and late life dementia with Lewy Bodies. No such association was found with late life Alzheimer’s disease. The conclusions suggest that possible associations between childhood ADHD and late life degenerative disease may be restricted to specific degenerative disease states.PubMedCrossRef

42.

Jicha GA, Schmitt FA, Abner E, et al. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging. 2010;31:1805–13.PubMedCrossRef

43.

Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2010;133:540–56.PubMedCrossRef

44.

Williams LM, Tsang TW, Clarke S, et al. An 'integrative neuroscience' perspective on ADHD: linking cognition, emotion, brain and genetic measures with implications for clinical support. Expert Rev Neurother. 2010;10:1607–21.PubMedCrossRef

45.

Hudziak JJ, Derks EM, Althoff RR, et al. The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales–Revised. Am J Psychiatry. 2005;162:1614–20.PubMedCrossRef

46.

Thapar A, Fowler T, Rice F, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003;160:1985–9.PubMedCrossRef

47.

Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.PubMedCrossRef

48.

Hudziak JJ, Heath AC, Madden PF, et al. Latent class and factor analysis of DSM-IV ADHD: a twin study of female adolescents. J Am Acad Child Adolesc Psychiatry. 1998;37:848–57.PubMedCrossRef

49.

Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–23.PubMedCrossRef

50.

Greven CU, Rijsdijk FV, Plomin R. A twin study of ADHD symptoms in early adolescence: hyperactivity-impulsivity and inattentiveness show substantial genetic overlap but also genetic specificity. J Abnorm Child Psychol. 2011;39:265–75.PubMedCrossRef

51.

Boomsma DI, Saviouk V, Hottenga JJ, et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One. 2010;5:e10621.PubMedCrossRef

52.

Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–3.PubMedCrossRef

53.

Genro JP, Kieling C, Rohde LA, et al. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses. Expert Rev Neurother. 2010;10:587–601.PubMedCrossRef

54.

Lauzon NM, Laviolette SR. Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: implications for neuropsychiatric disorders. Behav Brain Res. 2010;208:12–22.PubMedCrossRef

55.

Steinhausen HC. The heterogeneity of causes and courses of attention-deficit/hyperactivity disorder. Acta Psychiatr Scand. 2009;120:392–9.PubMedCrossRef

56.

Banaschewski T, Becker K, Scherag S, et al. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry. 2010;19:237–57.PubMedCrossRef

57.

Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2010;33:159–80.PubMedCrossRef

58.

Lo-Castro A, D'Agati E, Curatolo P. ADHD and genetic syndromes. Brain Dev. 2010.

59.

Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436–41.PubMedCrossRef

60.

Lee JH, Cheng R, Barral S, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol. 2011;68:320–8.PubMedCrossRef

61.

Castellanos FXL, Patti P; Sharp W, Jeffries, NO, Greenstein, DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA. 2002;288(14):1740–8.

62.

Strohle A, Stoy M, Wrase J, et al. Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder. NeuroImage. 2008;39:966–72.PubMedCrossRef

63.

Vaidya CJB, Silvia A, Dudukovic NM, Zalecki CA, Elliott GR, Grabieli JDE. Altered neural substrates of cognitive control in childhood adhd: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2005;162:1605–13.PubMedCrossRef

64.

• Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis. 2010;19:253–72. This thorough review of AD tracks the biological and clinical phenotype through its course from preclinical AD in cognitively normal individuals to mild cognitive impairment (MCI) to more fulminate AD. It provides an excellent background understanding of the key issues related to late life cognitive decline of the AD-type for the lay practitioner with expertise in ADHD but not in late life degenerative disorders.PubMed

65.

Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999;46:1234–42.PubMedCrossRef

66.

Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29:656–79.PubMedCrossRef

67.

Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry. 2009;43:101–8.PubMedCrossRef

68.

Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397–409.PubMedCrossRef

69.

Russell VA. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods. 2007;161:185–98.PubMedCrossRef

70.

Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry. 2007;62:1059–61.PubMedCrossRef

71.

Chamberlain SR, Muller U, Blackwell AD, et al. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology. 2006;188:397–407.PubMedCrossRef

72.

Kim CH, Waldman ID, Blakely RD, et al. Functional gene variation in the human norepinephrine transporter: association with Attention Deficit Hyperactivity Disorder. Ann N Y Acad Sci. 2008;1129:256–60.PubMedCrossRef

73.

Oades RD, Sadile AG, Sagvolden T, et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic, and interactive roles. Dev Sci. 2005;8:122–31.PubMedCrossRef

74.

Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy. 2004;24:1020–36.PubMedCrossRef

75.

Dell’Agnello G, Zuddas A, Masi G, et al. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs. 2009;23:739–53.PubMedCrossRef

76.

Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11:203–26.PubMedCrossRef

77.

Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006;20:713–38.PubMedCrossRef

78.

Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, et al. Pharmacological models of ADHD. J Neural Transm. 2008;115:287–98.PubMedCrossRef

79.

Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(Suppl):S46–53.PubMedCrossRef

80.

Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21:2042–51.PubMedCrossRef

81.

Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl. 2006:99–103.

82.

• Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9. This recent pathological analysis of AD changes demonstrates that the earliest appearance of AD-related changes is in the locus coeruleus, and that such changes can occur in childhood, adolescence, and early adulthood, when ADHD emerges as a clinical entity. This pathological finding is novel and supports a possible link between a hypo-aminergic state caused by AD and the clinical manifestations of ADHD.PubMedCrossRef

83.

Biederman J, Mick E, Faraone S, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006;26:163–6.PubMedCrossRef

84.

Doyle RL, Frazier J, Spencer TJ, et al. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9:543–9.PubMedCrossRef

85.

Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother. 2007;7:195–201.PubMedCrossRef

86.

Niederhofer H. Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine. Med Hypotheses. 2011;76:764–5.PubMedCrossRef

87.

Spencer T, Biederman J. Non-stimulant treatment for attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl):S109–19.PubMed

88.

Wilens TE, Biederman J, Wong J, et al. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000;10:217–22.PubMedCrossRef

89.

Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44:1624–32.PubMedCrossRef

90.

Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? Paediatr Drugs. 2010;12:165–75.PubMedCrossRef

91.

Darvill Jr FT, Woolley S. Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients. J Am Med Assoc. 1959;169:1739–41.PubMedCrossRef

92.

Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997;9:231–9.PubMed

93.

Goforth HW, Konopka L, Primeau M, et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci. 2004;35:108–11.PubMed

94.

Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28:296–301.PubMedCrossRef

95.

Kittur S, Hauser P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. Am J Psychiatry. 1999;156:1116–7.PubMed

96.

Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18:371–4.PubMedCrossRef

97.

Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.PubMedCrossRef

98.

Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci. 1995;7:502–4.PubMed

99.

Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2011.

100.

Cubo E. Fernandez Jaen A, Moreno C, et al. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther. 2008;30:182–9.PubMedCrossRef

Titel: Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment
verfasst von: Nikki Ivanchak
Kristen Fletcher
Gregory A. Jicha
Publikationsdatum: 01.10.2012
Verlag: Current Science Inc.
Erschienen in: Current Psychiatry Reports / Ausgabe 5/2012
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-012-0305-8

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment

Abstract

Neu im Fachgebiet Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Update Psychiatrie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Personalized Treatment of Alcohol Dependence

Obstructive Sleep Apnea and Severe Mental Illness: Evolution and Consequences

Current Status of Neurofeedback for Attention-Deficit/Hyperactivity Disorder

Polypharmacy in Attention Deficit Hyperactivity Disorder Treatment: Current Status, Challenges and Next Steps

Emerging Support for a Role of Exercise in Attention-Deficit/Hyperactivity Disorder Intervention Planning

Management of Post-Traumatic Nightmares: A Review of Pharmacologic and Nonpharmacologic Treatments Since 2010

Neu im Fachgebiet Psychiatrie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Update Psychiatrie